Glaukos Corporation vs Merck & Company, Inc. — Stock Comparison
Glaukos Corporation (GKOS) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Glaukos Corporation on Q·Score (7 vs 5.9 out of 10), led by Quality (7.7 vs 1.1) and Valuation (6.7 vs 5). Glaukos Corporation scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for GKOS (+22.7%) than for MRK (+12.4%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-34% margin).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
GKOS vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Glaukos Corporation (GKOS) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: GKOS or MRK?
Glaukos Corporation (GKOS) scores higher on Growth (7.4/10 vs 6.2/10). Glaukos Corporation reports revenue growth (41.2% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is GKOS or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.7/10 vs 5/10). GKOS trades at 287.2× P/E versus MRK at 12.1×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about GKOS vs MRK?
There are 12 analysts covering GKOS with a consensus price target of $156.33, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: GKOS or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 1.1/10). Net profit margin: GKOS at -34.3%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: GKOS or MRK?
Glaukos Corporation (GKOS) scores higher on Financial Health (9.2/10 vs 7/10). Market beta: GKOS at 0.81, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of GKOS and MRK?
Glaukos Corporation (GKOS) has a market capitalisation of $7.5B, while Merck & Company, Inc. (MRK) has a market cap of $285.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do GKOS or MRK pay dividends?
GKOS does not currently pay a dividend, while MRK pays a dividend yield of 2.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →